drugset / Trial / NCT05770882
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
NaSequentialOpen-labelTreatment
Summary
This open-label, phase Ib/II, multicenter study evaluated the safety, tolerability, efficacy, and PK of chidamide in combination with regorafenib in patients with HCC. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor. Regorafenib, a receptor tyrosine kinase inhibitor, was approved as second-line systemic treatment for HCC patients.
Timeline
- Start
- 2023-04-25
- Primary completion
- 2025-01-17
- Completion
- 2025-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 40 mg | — |
| Subject | Tucidinostat | Small molecule | 5 mg | — |